Cardiotonic Agents Market Size - Growth by 2031
The Cardiotonic Agents Market is expected to register a CAGR of 21.4% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX million by 2031.
The report is segmented by OTC Consumer Healthcare Market By Drug Type (Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, and Others); Application (Cardiac Surgical Procedures, Atrial Fibrillation, Heart Failure, Pulmonary Hypertension, and Others); Route of Administration (Oral and Parenteral); Dosage Form (Tablet, Solutions, and Others); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) , and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America). The global analysis is further broken-down at regional level and major countries. The Report Offers the Value in USD for the above analysis and segments.
Purpose of the ReportThe report Cardiotonic Agents Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Cardiotonic Agents Market Segmentation
Drug Type- Digitalis Glycosides
- Phosphodiesterase Inhibitors
- Cardioprotectants
- Sympathomimetic Agents
- Others
- Cardiac Surgical Procedures
- Atrial Fibrillation
- Heart Failure
- Pulmonary Hypertension
- Others
- Oral and Parenteral
- Tablet
- Solutions
- Others
- Tablet
- Solutions
- Others
Strategic Insights
Cardiotonic Agents Market Growth Drivers- Increasing Prevalence of Cardiovascular Diseases:The prevalence of cardiovascular diseases (CVDs) is rising worldwide, and it is predicted that more than 6.5 million North Americans will have heart failure by 2030. The need for efficient treatment options, such as cardiotonic medicines, is fueled by this expanding patient population.
- Aging Population: The necessity for cardiotonic therapy is further increased by the fact that an older population is more prone to heart-related illnesses. Age-related cardiovascular problems are more common as life expectancy rises, which drives market expansion.Such a factor has assisted the overall market growth in the recent past and is expected to continue a similar trend during the forecast period.
- Rising Healthcare Investments:The development and accessibility of sophisticated cardiotonic therapies are facilitated by higher healthcare spending in areas such as North America. Improved access to these drugs is made possible by improved healthcare infrastructure, which fuels market expansion.Such a factor has assisted the overall market growth in the recent past and is expected to continue a similar trend during the forecast period.
- Government Support:The market for cardiotonic agents is also supported by a number of government programs that use money and public health campaigns to improve cardiovascular health. These efforts frequently include of funding for studies and campaigns raising awareness of heart health.
- Patient Education:Demand is being driven by patients' and healthcare professionals' growing awareness of cardiovascular illnesses and diseases and the advantages of cardiotonic medications. Campaigns for education assist in educating stakeholders about the value of various medicines in the management of cardiac diseases.
- Medical Community Advocacy:Cardiotonic drugs are becoming more widely accepted and used in clinical practice as a result of the medical community's increased focus on their advantages in treating heart failure and other cardiovascular disorders. Cardiotonic medications are in greater demand as part of post-COVID care regimens because of the COVID-19 pandemic's increased reporting of cardiovascular problems among recovered patients. As healthcare systems adjust to the pandemic's long-term consequences on heart health, this tendency is anticipated to continue.
- Personalized Medicine:Medical practitioners can find particular genetic markers linked to heart failure and other cardiovascular disorders through genetic testing. This makes it possible to create individualized treatment programs that maximize the use of cardiotonic medicines, increasing their effectiveness and lowering their side effects. Because personalized treatments are more likely to provide favorable results, there is a greater need for cardiotonic medicines that are suited to the demands of specific patients.
- Enhanced Drug Selection: Clinicians can choose the best cardiotonic medicines by knowing a patient's hereditary susceptibility to specific cardiovascular diseases. Genetic testing is a useful tool in directing therapeutic decisions since, for instance, people with particular genetic variants may respond better to various drugs.
- Predictive Insights:A patient's risk of heart failure or poor response to conventional therapy can be inferred from genetic testing. Early intervention with cardiotonic medicines is made possible by this predictive skill, which may enhance patient outcomes and quality of life.Such a factor has assisted the overall market growth in the recent past and is expected to continue a similar trend during the forecast period.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Cardiotonic Agents Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Cardiotonic Agents Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORKHave a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
In Europe, the UK held the second largest share in 2023.
Personalized Medicine
Asia pacific region is expected to witness the highest growth during the forecast period
Personalized Medicine
North America held the largest share in 2023 and is expected to retain its dominance during the forecast period
The Cardiotonic Agents Market is estimated to witness a CAGR of 21.4% from 2023 to 2031
Table of Content
1. Introduction
1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness Analysis
3. Research Methodology
4. Cardiotonic Agents market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
4.3.1 List of Vendors in the Value Chain
5. Cardiotonic Agents market - Key Market Dynamics
5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints
6. Cardiotonic Agents market - Global Market Analysis
6.1 Cardiotonic Agents market - Global Market Overview
6.2 Cardiotonic Agents market - Global Market and Forecast to 2030
7. Cardiotonic Agents market - Revenue Analysis (USD Million) - By Drug Type, 2020-2030
7.1 Overview
7.2 Digitalis Glycosides
7.3 Phosphodiesterase Inhibitors
7.4 Cardioprotectants
7.5 Sympathomimetic Agents
7.6 Others
8. Cardiotonic Agents market - Revenue Analysis (USD Million) - By Application, 2020-2030
8.1 Overview
8.2 Cardiac Surgical Procedures
8.3 Atrial Fibrillation
8.4 Heart Failure
8.5 Pulmonary Hypertension
8.6 Others
9. Cardiotonic Agents market - Revenue Analysis (USD Million) - By Route of Administration, 2020-2030
9.1 Overview
9.2 Oral
9.3 Parenteral
10. Cardiotonic Agents market - Revenue Analysis (USD Million) - By Dosage Form, 2020-2030
10.1 Overview
10.2 Tablet
10.3 Solutions
10.4 Others
11. Cardiotonic Agents market - Revenue Analysis (USD Million) - By Distribution Channel, 2020-2030
11.1 Overview
11.2 Hospital Pharmacies
11.3 Retail Pharmacies
11.4 Online Pharmacies
12. Cardiotonic Agents market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis
12.1 North America
12.1.1 North America Cardiotonic Agents market Overview
12.1.2 North America Cardiotonic Agents market Revenue and Forecasts to 2030
12.1.3 North America Cardiotonic Agents market Revenue and Forecasts and Analysis - By Drug Type
12.1.4 North America Cardiotonic Agents market Revenue and Forecasts and Analysis - By Application
12.1.5 North America Cardiotonic Agents market Revenue and Forecasts and Analysis - By Route of Administration
12.1.6 North America Cardiotonic Agents market Revenue and Forecasts and Analysis - By Dosage Form
12.1.7 North America Cardiotonic Agents market Revenue and Forecasts and Analysis - By Distribution Channel
12.1.8 North America Cardiotonic Agents market Revenue and Forecasts and Analysis - By Countries
12.1.8.1 United States Cardiotonic Agents market
12.1.8.1.1 United States Cardiotonic Agents market, by Drug Type
12.1.8.1.2 United States Cardiotonic Agents market, by Application
12.1.8.1.3 United States Cardiotonic Agents market, by Route of Administration
12.1.8.1.4 United States Cardiotonic Agents market, by Dosage Form
12.1.8.1.5 United States Cardiotonic Agents market, by Distribution Channel
12.1.8.2 Canada Cardiotonic Agents market
12.1.8.2.1 Canada Cardiotonic Agents market, by Drug Type
12.1.8.2.2 Canada Cardiotonic Agents market, by Application
12.1.8.2.3 Canada Cardiotonic Agents market, by Route of Administration
12.1.8.2.4 Canada Cardiotonic Agents market, by Dosage Form
12.1.8.2.5 Canada Cardiotonic Agents market, by Distribution Channel
12.1.8.3 Mexico Cardiotonic Agents market
12.1.8.3.1 Mexico Cardiotonic Agents market, by Drug Type
12.1.8.3.2 Mexico Cardiotonic Agents market, by Application
12.1.8.3.3 Mexico Cardiotonic Agents market, by Route of Administration
12.1.8.3.4 Mexico Cardiotonic Agents market, by Dosage Form
12.1.8.3.5 Mexico Cardiotonic Agents market, by Distribution Channel
Note - Similar analysis would be provided for below mentioned regions/countries
12.2 Europe
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 Spain
12.2.5 United Kingdom
12.2.6 Rest of Europe
12.3 Asia-Pacific
12.3.1 Australia
12.3.2 China
12.3.3 India
12.3.4 Japan
12.3.5 South Korea
12.3.6 Rest of Asia-Pacific
12.4 Middle East and Africa
12.4.1 South Africa
12.4.2 Saudi Arabia
12.4.3 U.A.E
12.4.4 Rest of Middle East and Africa
12.5 South and Central America
12.5.1 Brazil
12.5.2 Argentina
12.5.3 Rest of South and Central America
13. Pre and Post Covid-19 Impact
14. Industry Landscape
14.1 Mergers and Acquisitions
14.2 Agreements, Collaborations, Joint Ventures
14.3 New Product Launches
14.4 Expansions and Other Strategic Developments
15. Competitive Landscape
15.1 Heat Map Analysis by Key Players
15.2 Company Positioning and Concentration
16. Cardiotonic Agents market - Key Company Profiles
16.1 Amneal Pharmaceuticals LLC
16.1.1 Key Facts
16.1.2 Business Description
16.1.3 Products and Services
16.1.4 Financial Overview
16.1.5 SWOT Analysis
16.1.6 Key Developments
Note - Similar information would be provided for below list of companies
16.2 Pfizer Inc.,
16.3 Hikma Pharmaceuticals PLC
16.4 Fresenius Kabi
16.5 Midas Pharma GmbH
16.6 Sanofi
16.7 Aurobindo Pharma Limited
16.8 SimSon Pharma Limited
16.9 Novartis AG
16.10 Merck and Co. Inc.
17. Appendix
17.1 Glossary
17.2 About The Insight Partners
17.3 Market Intelligence Cloud
The List of Companies
1. Amneal Pharmaceuticals LLC
2. Pfizer Inc.
3. Hikma Pharmaceuticals PLC
4. Fresenius Kabi
5. Midas Pharma GmbH
6. Sanofi
7. Aurobindo Pharma Limited
8. SimSon Pharma Limited.
9. Novartis
10. Merck & Co. Inc.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.